OMALIZUMAB

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

CHRONIC SPONTANEOUS URTICARIA

Conditions

CHRONIC SPONTANEOUS URTICARIA

Trial Timeline

Apr 22, 2015 → Jan 11, 2016

NCT ID

NCT02550106

About OMALIZUMAB

OMALIZUMAB is a approved stage product being developed by Novartis for CHRONIC SPONTANEOUS URTICARIA. The current trial status is completed. This product is registered under clinical trial identifier NCT02550106. Target conditions include CHRONIC SPONTANEOUS URTICARIA.

What happened to similar drugs?

20 of 20 similar drugs in CHRONIC SPONTANEOUS URTICARIA were approved

Approved (20) Terminated (3) Active (0)

✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved

✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved

✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved

✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved

✅alefaceptAstellas PharmaApproved

✅AlefaceptAstellas PharmaApproved

✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05424523	Pre-clinical	Completed	Feb 25, 2021	Jun 28, 2021	Allergic Asthma
NCT05157087	Pre-clinical	Completed	Mar 1, 2020	Dec 1, 2020	Asthma
NCT04037176	Approved	Completed	Nov 1, 2019	Mar 15, 2022	Food Allergy
NCT02550106	Approved	Completed	Apr 22, 2015	Jan 11, 2016	CHRONIC SPONTANEOUS URTICARIA
NCT02329223	Phase 3	Completed	Dec 1, 2014	Dec 1, 2015	Chronic Spontaneous Uriticaria
NCT02262130	Phase 2	Completed	Sep 30, 2014	Sep 29, 2015	Solar Urticaria
NCT02118987	Phase 1	Completed	Jul 1, 2014	Dec 1, 2017	Drug Allergy
NCT02023151	Approved	Completed	Feb 1, 2013	Aug 1, 2016	Allergic Asthma
NCT01328886	Phase 3	Completed	Mar 1, 2011	Dec 1, 2013	Allergic Asthma
NCT01155700	Phase 3	Completed	Jun 1, 2010	Feb 1, 2012	Allergic Asthma
NCT00500539	Phase 3	Completed	Jul 1, 2007	Sep 1, 2008	Asthma
NCT00264849	Approved	Completed	Nov 1, 2005	Sep 1, 2008	Asthma
NCT00180011	Phase 2/3	Completed	Sep 1, 2005	Feb 1, 2012	Asthma
NCT00639691	Approved	Completed	Jan 1, 2005	Dec 1, 2011	Asthma
NCT00226200	Pre-clinical	Terminated	Nov 1, 2004	Oct 1, 2007	Asthma
NCT00482248	Phase 3	Completed	Jun 1, 2003	Jun 1, 2006	Asthma
NCT00482508	Phase 3	Completed	May 1, 2003	Oct 1, 2005	Asthma
NCT00046748	Phase 3	Completed	Dec 1, 2001	Apr 1, 2004	Asthma

Competing Products

20 competing products in CHRONIC SPONTANEOUS URTICARIA

See all competitors

Product	Company	Stage	Hype Score
Levofloxacin 500	Dr. Reddy's Laboratories	Pre-clinical	23
mRNA-0184	Moderna	Phase 1	0
Lubiprostone + Lubiprostone + Placebo	Dr. Reddy's Laboratories	Phase 3	37
macitentan 10 mg	BML, Inc.	Phase 3	32
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
TERN-701	Terns Pharmaceuticals	Phase 1/2	36
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	23
LY3556050 + Placebo	Eli Lilly	Phase 2	35
THB001	Third Harmonic Bio	Phase 1	11
Briquilimab	Jasper Therapeutics	Phase 1/2	26
Briquilimab	Jasper Therapeutics	Phase 1/2	14
Briquilimab	Jasper Therapeutics	Phase 2	29
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	40
LY3461767 + Placebo	Eli Lilly	Phase 1	29
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	44
LY3526318 + Placebo	Eli Lilly	Phase 2	35
Pirtobrutinib	Eli Lilly	Phase 2	42
Ibrutinib + LY3214996	Eli Lilly	Phase 1	21
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	27
LYR-210	Lyra Therapeutics	Phase 2	25